- recruiting
A clinical trial to find out if using the findings from PSMA PET scans to escalate treatment can improve cancer control in patients with high-risk prostate cancer
This study looks at new scans (PSMA PET-CT) for men with high-risk prostate cancer. We want to see if using these scans to guide treatment can help control the cancer better than standard scans. It could improve future care for prostate cancer patients.
United Kingdom - completedPhase I
A study of Pasritamig (JNJ-78278343) in combination with JNJ-86974680 for treatment of prostate cancer
This study is testing two new drugs, Pasritamig and JNJ-86974680, together for men with advanced prostate cancer. Researchers want to find the safest dose and see if it helps fight the cancer. It's a very early-stage trial.
United Kingdom · England · United States of America - active not recruiting
Using Breath, Cell Free DNA and Image Analysis to PRedIct Normal TissUe and Tumour Response During Prostate Cancer SBRT
This study aims to make prostate radiotherapy treatment more personal. We're looking at breath, DNA, and scans to predict how well your body and the cancer respond to treatment. The goal is to improve cure rates and reduce side effects during a 5-day radiotherapy course.
United Kingdom - active not recruitingNA
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
This study looks at how well a product called SpaceOAR Vue helps men with prostate cancer. It aims to reduce gut problems when they have a type of radiation treatment called SBRT, by putting a special gel between the prostate and bowel.
United States · Australia · France - active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
United States · Argentina · Australia - active not recruitingPHASE3
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
This study looks at a new drug called darolutamide, along with standard treatments like radiotherapy and hormone therapy, for men with prostate cancer that's at a very high risk of coming back. The aim is to see if this combination can better stop the cancer from spreading and improve their long-term health.
United States · Australia · Canada - active not recruitingPHASE3
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
This study looks at a new combination of medicines, enzalutamide and leuprolide, for men with prostate cancer that hasn't spread but is considered high-risk. The goal is to see how safe and effective this combination is in slowing down the cancer.
United States · Australia · Austria - recruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
United States · Argentina · Australia - recruiting
Selecting Hypoxic Tumours for Treatment Modification
This study aims to find better ways to treat bladder and prostate cancers that are hard to cure with standard radiotherapy. We are testing a new method to identify these 'hard-to-treat' tumours so doctors can choose the best treatment for each patient.
United Kingdom - ongoing, recruitingTherapeutic use (Phase IV)
Determining the clinical relevance of the interaction between enzalutamide and the opioid morphine and the DOAC edoxaban to improve rational pharmacological care of patients with prostate cancer
This study looks at how a prostate cancer drug, enzalutamide, might affect other medicines like morphine (for pain) and edoxaban (a blood thinner). The aim is to make sure patients get the best and safest care when taking these drugs together.
Netherlands - authorisedTherapeutic exploratory (Phase II)
Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts
This study is looking at a new way to treat prostate cancer that has spread. It compares two different drug combinations to see which is better at stopping the cancer from growing for at least four months.
Italy - recruitingPHASE3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study looks at a new drug, mevrometostat, combined with enzalutamide for men with prostate cancer that has spread. It compares this combination to enzalutamide alone, to see if it works better for those not yet treated with specific hormone therapies.
United States · Argentina · Australia - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.
This study looks at a new way to treat prostate cancer that has spread to the bones. It combines two types of radiation treatment, Lutetium-177 PSMA and Radium-223, given one after the other. We want to see if this treatment is safe and practical for men after their initial cancer treatment.
Netherlands - active not recruitingNA
Prostate Cancer Active Surveillance Trigger Trial (PCASTT-UK): Comparing Current Practice for Men With Prostate Cancer on Active Surveillance (AS) to an AS Protocol With Standardised Triggers for Transitioning to Curative Treatment
This study compares current care for prostate cancer patients on active surveillance with a new approach. It aims to find the best time to start treatment to prevent cancer from getting worse, without giving unnecessary treatment or causing side effects.
United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 160 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subjects under fasting condition.
This study is comparing a new version of the prostate cancer drug Enzalutamide with the original one. It's looking at how well healthy men absorb the new drug to make sure it works the same way.
Romania - authorisedTherapeutic exploratory (Phase II)
Efficacy and safety of cannabidiol for pain relief of patients with end-stage metastatic castration resistant prostate cancer - a randomised double-blinded placebo-controlled phase II trial (ProCan)
This study is looking at whether a cannabis-based medicine called cannabidiol (CBD) can help men with advanced prostate cancer manage their pain and possibly reduce their need for strong painkillers. We want to see if CBD is safe and effective compared to a dummy treatment.
Denmark - authorisedPhase I and Phase II (Integrated)- Other
Sequential Chemotherapy regimen with vinorelbine and cisplatin plus PET-guided stereotactic ablative radiotherapy (SABR) for castration- and taxane-resistant Prostate cancer (ChemSABR Prostate)
This study is for men with prostate cancer that hasn't responded to usual treatments. It's testing a new approach using chemotherapy drugs (vinorelbine and cisplatin) followed by special radiation therapy (SABR). Researchers want to see if this combination is safe and effective.
Estonia - recruiting
NEWPROMRI-PATHWAY - A New Prostate Magnetic Resonance Imaging (MRI) Pathway
This study looks at new ways to use MRI scans for prostate cancer. We want to see if specially trained radiographers, supported by a computer system, can help more men get timely and effective prostate cancer diagnoses without unnecessary procedures like contrast injections or multiple appointments.
United Kingdom - recruitingNot Applicable
SpaceOAR post-market registry study
This study looks at the long-term safety of SpaceOAR, a gel that protects men from radiation side effects during prostate cancer therapy. It collects health information from men in the UK who are already receiving SpaceOAR as part of their normal care.
United Kingdom · England - active not recruiting
The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.
This study looks at using a genetic test to help decide who needs prostate cancer screening. It uses a saliva sample to check for genetic differences that might increase your risk. If your risk is high, you might be offered further tests like an MRI scan and a biopsy.
United Kingdom - active not recruitingPHASE3
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
This study looks at treating advanced prostate cancer with radiation and hormone therapy. It compares two types of hormone therapy to see which is better at stopping the cancer from growing, spreading, or coming back.
Belgium · Denmark · France - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - recruiting
A multi-centre, non-interventional study of relugolix in patients with advanced hormone-sensitive prostate cancer
This study looks at how a prostate cancer medicine called relugolix works in real life. It's for men whose doctor has already decided relugolix is the right treatment. Researchers will gather information from routine doctor visits to understand its effects, without changing participants' care.
United Kingdom · England · France - recruitingPHASE1, PHASE2
ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
This study is testing a new radioactive drug called Actinium (225Ac) rhPSMA-10.1 for men with advanced prostate cancer that has spread. It aims to find a safe dose and see how well it works, especially for those who've already had a similar treatment.
United Kingdom - active not recruitingPHASE2
Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
This study is testing different doses of two drugs, nivolumab and ipilimumab, for men with advanced prostate cancer that has stopped responding to standard treatments. It focuses on patients whose cancer has certain genetic ‘signatures’ that might make them more likely to respond to this type of treatment.
United Kingdom - active not recruitingPHASE2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This study is testing a new drug, PF-07220060, for people with advanced cancers like breast, prostate, and lung cancer. Researchers want to see if it's safe and how it works, both by itself and with other cancer medicines.
United States · Argentina · China - recruitingNA
The Man Van Project
The Man Van project offers mobile health checks at workplaces and communities for men, especially those from ethnic minority groups, to find health problems like prostate cancer early. The goal is to make healthcare easier to access and improve men's health outcomes.
United Kingdom - recruitingNA
Focal Therapy for Prostate Cancer Using HIFU
This study is looking at an advanced treatment called 'focal therapy' using HIFU for prostate cancer. It aims to see how well it controls cancer while reducing side effects like erection problems and bladder issues, which are common with other treatments.
United Kingdom - active not recruiting
Exploiting Risk-Based Risk Stratification in Early Prostate Cancer to Discriminate Progressors From Non-Progressors
This study looks at men with early prostate cancer to understand why some cancers grow and others don't. Researchers will use MRI scans and samples over time to find differences between progressive and non-progressive cancers, aiming to improve future treatment decisions.
United Kingdom - ongoing, recruitingTherapeutic confirmatory (Phase III)
Prospective Study of Added Value of Florastamin (18F) PET/CT in Localisation of Clinically Significant Prostate Cancer in Patients with PI- Report of Multi-Parametric MRI, Elevated Serum PSA Levels and/or PSA Density and with Clinical Suspicion of Prostate Cancer
This study is looking at a new imaging test, called Prostavue, for men who might have prostate cancer. It wants to see how well Prostavue can find prostate cancer and help doctors decide on the best treatment plan.
Austria - recruitingNot Specified
Aiming to understand how the primary tumour in the prostate, and the treatment of this, can affect secondary tumours at other sites
This study looks at how treating the main prostate cancer tumour can affect any cancer that has spread. We want to find better ways to treat advanced prostate cancer and stop it from becoming resistant to medicines.
United Kingdom · England - recruitingNA
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions
This study looks at a new, very short course of radiotherapy for prostate cancer, given in just two treatments. We want to see if different ways of targeting the dose can reduce side effects while still controlling the cancer.
Canada · United Kingdom - active not recruitingPHASE1, PHASE2
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This study is looking into a new drug, AZD5305, by itself or with other cancer treatments, for advanced solid cancers like ovarian, breast, and lung cancer. It aims to see if it's safe, tolerable, and effective.
United States · Australia · Canada - active not recruitingPHASE2
Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms
This study looks at new ways to treat prostate cancer that has spread. It compares adding treatments directly to the prostate and other affected areas with standard care, to see if it improves outcomes for men who have recently been diagnosed.
United Kingdom - authorisedPhase I and Phase II (Integrated)- First administration to humans
99mTechnetium and Cyanine-5 (HybriD) Prostate Specific Membrane Antigen (PSMA) Tracer-gUided Surgery in ProstAte Cancer - a FeasibiLity Study (DUAL study)
This study looks at a new way to help surgeons find prostate cancer more easily during operations. It uses a special tracer that lights up cancer cells. This could help surgeons remove all the cancer and improve treatment for men with prostate cancer.
Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 80 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subjects under fasting condition.
This study is comparing two versions of a prostate cancer medicine called enzalutamide in healthy men. It wants to see if a new generic version works the same way in the body as the original one, to make sure it's just as effective.
Romania - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This study is testing a new drug, ST101, for people with advanced cancers like breast cancer, melanoma, and glioblastoma. It aims to see if the drug is safe, how much to give, and if it could help shrink tumors. It's for adults whose cancer hasn't responded to other treatments.
United States · United Kingdom - active not recruitingNA
SPCG17: Prostate Cancer Active Surveillance Trigger Trial
This study looks at how best to manage prostate cancer through 'active surveillance'. This means closely monitoring the cancer instead of immediate treatment. We want to find out if clear guidelines for monitoring can reduce unnecessary treatments while still keeping you safe.
Denmark · Finland · Norway - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China - recruitingPHASE2
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
This study looks at a new injection, ASP5541, for advanced prostate cancer that has spread. It compares ASP5541 to a standard tablet treatment, abiraterone acetate, to see how safe and effective it is.
United States · China · France - active not recruitingNA
Prostate Testing for Cancer and Treatment
This study, called 'Prostate Testing for Cancer and Treatment' (ProtecT), is looking at how different treatments for prostate cancer compare. It's for men aged 50-69 with early prostate cancer. Researchers want to see if surgery, radiation, or simply watching the cancer works best in the long run.
United Kingdom - recruitingNA
Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer
This study looks at new ways to find prostate cancer using MRI scans and biopsies. Researchers want to see if a shorter, simpler MRI is as good as the usual one, and if guiding biopsies with a computer is better than relying on a doctor’s eye.
United Kingdom - recruiting
The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study).
This study looks at a new saliva test, called i4i PRODICT®, to predict prostate cancer risk in men aged 40-55 from different ethnic backgrounds. It aims to see how well men accept and use this test.
United Kingdom - recruiting
Precision Medicine in the Prostate Cancer Care Pathway
This study looks at a special genetic test for prostate cancer. It helps men understand their personal risk and how this information can guide decisions about screening and treatment. The aim is to use genetic insights for more tailored prostate cancer care.
United Kingdom - active not recruitingPHASE1
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is testing a new cancer medicine, botensilimab, sometimes with another drug, balstilimab. It's for people with advanced cancers that haven't responded to other treatments. Doctors want to see if it's safe, how it works, and find the best dose.
United States · United Kingdom - recruitingPHASE2
TherApeutics in Early ProState Cancer (TAPS02)
This study is looking at a new way to treat early prostate cancer. It tests a drug called apalutamide (Erleada) in men who are already under careful watch for their cancer. We want to see if this short-term treatment can help.
United Kingdom - authorisedTherapeutic confirmatory (Phase III)
PSMA PET For intermediate- or high-risk prostate cancer prior to RadioTherapY: A prospective interventional randomized clinical trial (P4RTY)
This study looks at a special scan called PSMA PET for men with prostate cancer before radiotherapy. It aims to see if this scan helps manage their cancer better and improves their health over time compared to standard care.
Germany - recruiting
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
This study, called IRONMAN, is collecting information from men with advanced prostate cancer across many countries, including the UK. It aims to understand treatments, how they vary, and what helps men live longer and have a better quality of life.
United States · Australia · Barbados - recruiting
In Vivo Dosimetry for Brachytherapy Study
This study looks at using tiny devices to check radiation doses during brachytherapy for prostate or gynaecological cancer. The devices ensure patients receive the correct, planned amount of radiation inside their bodies, helping to make treatment safer and more effective.
United Kingdom